193 related articles for article (PubMed ID: 37647435)
1. Clinical efficacy, safety, and subjective experience based on ePRO in HIV-infected individuals administered Bictegravir/Emtricitabine/Tenofovir Alafenamide in southwest China.
Kong L; Xie X; Fu Y; Gan L; Yang X; Ma S; Long H
Immun Inflamm Dis; 2023 Aug; 11(8):e974. PubMed ID: 37647435
[TBL] [Abstract][Full Text] [Related]
2. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
[TBL] [Abstract][Full Text] [Related]
3. Bictegravir/Emtricitabine/Tenofovir Alafenamide in a Multicentre Cohort: Real-Life Experience From Spain.
Torralba M; Rodríguez G; González Gasca FJ; Cuadra F; Barberá J; Geijo P; Silva A; García MI; Ostaiza MA; García Pérez AM; Arroyo E; Larrubia JR; Gutiérrez A; Porras ML; Calvo Sánchez H; Peña-Asensio J; Arias JG; Mendoza I
Ann Pharmacother; 2024 Feb; 58(2):140-147. PubMed ID: 37131300
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide fumarate for adult patients with human immunodeficiency virus-1 in China: a retrospective real-world cohort study.
Gan L; Xie X; Fu Y; Song Y; Song C; Ren T; Long H
Expert Rev Anti Infect Ther; 2024 Apr; 22(4):211-217. PubMed ID: 38058002
[TBL] [Abstract][Full Text] [Related]
5. Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study.
Gan L; Xie X; Fu Y; Yang X; Ma S; Kong L; Song C; Song Y; Ren T; Long H
BMC Infect Dis; 2024 Jun; 24(1):565. PubMed ID: 38844855
[TBL] [Abstract][Full Text] [Related]
6. Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China.
Jing C; Wei T; Ning W; Fang Z; Gang X; Xingzhi W; Guoqiang Z; Min W
BMC Infect Dis; 2023 Jun; 23(1):396. PubMed ID: 37308847
[TBL] [Abstract][Full Text] [Related]
7. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
[TBL] [Abstract][Full Text] [Related]
8. Body mass index increase and weight gain among people living with HIV-1 initiated on single-tablet darunavir/cobicistat/emtricitabine/tenofovir alafenamide or bictegravir/emtricitabine/tenofovir alafenamide in the United States.
Emond B; Rossi C; Côté-Sergent A; Bookhart B; Anderson D; Lefebvre P; Lafeuille MH; Donga P
Curr Med Res Opin; 2022 Feb; 38(2):287-298. PubMed ID: 34812097
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in HIV late presenters.
Corona D; Pérez-Valero I; Camacho A; Gutiérrez Liarte Á; Montero-Alonso M; Alemán MR; Ruiz-Seco P; Pérez González A; Riera M; Jarrin I; Rivero-Juárez A; Rivero A
Int J Antimicrob Agents; 2024 Jan; 63(1):107016. PubMed ID: 37890734
[TBL] [Abstract][Full Text] [Related]
10. Increased human immunodeficiency virus viral load with cerebral infarction due to varicella zoster virus vasculopathy on treatment with bictegravir/emtricitabine/tenofovir alafenamide suspension: a case report and literature review.
Ishikawa K; Kawai F; Mori N
AIDS Res Ther; 2023 Jul; 20(1):53. PubMed ID: 37518182
[TBL] [Abstract][Full Text] [Related]
11. Bictegravir/emtricitabine/tenofovir alafenamide as first-line treatment in naïve HIV patients in a rapid-initiation model of care: BIC-NOW clinical trial.
Hidalgo-Tenorio C; Sequera S; Vivancos MJ; Vinuesa D; Collado A; Santos IL; Sorni P; Cabello-Clotet N; Montero M; Font CR; Terron A; Galindo MJ; Martinez O; Ryan P; Omar-Mohamed M; Albendín-Iglesias H; Javier R; Ruz MÁL; Romero A; Garcia-Vallecillos C
Int J Antimicrob Agents; 2024 Jun; 63(6):107164. PubMed ID: 38574873
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A; Tavelli A; Di Biagio A; Sarmati L; Marchetti GC; Bai F; Cingolani A; Quiros Roldan E; Mussini C; Lichtner M; Vergori A; Piconi S; Orofino G; Fusco FM; Bandera A; Nozza S; Castagna A; Antinori A;
J Antimicrob Chemother; 2024 Jun; 79(6):1279-1288. PubMed ID: 38581349
[TBL] [Abstract][Full Text] [Related]
13. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
Podzamczer D; Imaz A; Lopez-Lirola A; Knobel H; Masiá M; Fanciulli C; Hernández C; Lagarde M; Gutierrez A; Curran A; Morano L; Montero-Alonso M; Troya J; Rigo R; Casadellà M; Navarro-Alcaraz A; Ardila F; Parera M; Bernal E; Echeverria P; Estrada V; Hidalgo-Tenorio C; Macias J; Prieto P; Portilla J; Valencia E; Vivancos MJ; Rivero A
J Antimicrob Chemother; 2023 Nov; 78(11):2696-2701. PubMed ID: 37725999
[TBL] [Abstract][Full Text] [Related]
14. Reasons, safety and efficacy analysis for conversion of HAART to TAF/FTC/BIC among HIV-infected patients.
Xiao J; Gao G; Ding Y; Li J; Gao C; Xu Q; Wu L; Liang H; Ni L; Wang F; Duan Y; Yang D; Zhao H
Chin Med J (Engl); 2023 Dec; 136(24):2931-2937. PubMed ID: 38032036
[TBL] [Abstract][Full Text] [Related]
15. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
Rowe SM; Clary JC; Drummond M; Derrick C; Sanasi K; Bookstaver PB
Am J Health Syst Pharm; 2022 Aug; 79(16):1330-1336. PubMed ID: 35511892
[TBL] [Abstract][Full Text] [Related]
16. Real-life experience with bictegravir/emtricitabine/tenofovir alafenamide in a large reference clinical centre.
Ambrosioni J; Rojas Liévano J; Berrocal L; Inciarte A; de la Mora L; González-Cordón A; Martínez-Rebollar M; Laguno M; Torres B; Ugarte A; Chivite I; Leal L; de Lazzari E; Miró JM; Blanco JL; Martinez E; Mallolas J
J Antimicrob Chemother; 2022 Mar; 77(4):1133-1139. PubMed ID: 35040990
[TBL] [Abstract][Full Text] [Related]
17. Efficacy, durability, and tolerability of bictegravir/emtricitabine/tenofovir alafenamide for the treatment of HIV in a real-world setting in Belgium.
Nasreddine R; Florence E; Yombi JC; Henrard S; Darcis G; Van Praet J; Vandekerckhove L; Allard SD; Demeester R; Messiaen P; Ausselet N; Delforge M; De Wit S;
HIV Med; 2023 Aug; 24(8):914-924. PubMed ID: 37038245
[TBL] [Abstract][Full Text] [Related]
18. Bictegravir/emtricitabine/tenofovir alafenamide plus doravirine in highly treatment-experienced men with multidrug-resistant HIV.
Sterman FL; Lalezari JP; Kowalczyk UM; Main DW; Grant EM; Caro L; Manning CM; Burke RL
AIDS; 2023 Jun; 37(7):1057-1064. PubMed ID: 36927740
[TBL] [Abstract][Full Text] [Related]
19. Treatment-emergent reverse transcriptase resistance during antiretroviral therapy with bictegravir, tenofovir alafenamide, and emtricitabine: A case series.
DeKoven S; Naccarato M; Brumme CJ; Tan DHS
HIV Med; 2023 Nov; 24(11):1137-1143. PubMed ID: 37317505
[TBL] [Abstract][Full Text] [Related]
20. [Effectiveness, safety, and economic impact of the bictegravir/emtricitabine/tenofovir alafenamide regimen in real clinical practice cohort of HIV-1 infected adult patients].
Gutiérrez-Lorenzo M; Rubio-Calvo D; Urda-Romacho J
Rev Esp Quimioter; 2021 Aug; 34(4):315-319. PubMed ID: 34032111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
